Cell & Gene Therapy
Cell & Gene Control Towers
In four strategic locations across the globe, Marken’s state-of-the-art monitoring facilities provide full visibility of all cell and gene therapy shipments anywhere in the world. The Cell and Gene Control Tower is Marken’s latest service investment to further enhance our ability to provide flawless execution and expert support for these ultra-sensitive shipments.
Our Cell and Gene Control Center offers 24/7/365 visibility into cell and gene therapy shipments, enabling improved chain of custody and enhanced quality control to ensure sites and patients are receiving these medicines in an efficient and timely manner.
Our dedicated staff of cell and gene supply chain experts will monitor weather, flight delays, and other potential risks to make critical path decisions and ensure flawless execution of every shipment. Combined with our global network of liquid nitrogen storage facilities and fourteen designated Centers of Excellence for cell and gene therapy logistics across the U.S., Europe, and Asia, Marken’s facilities are strategically located to complete an end-to-end cell and gene therapy supply chain service for our clients.
Only Marken delivers the end-to-end capabilities and expert oversight needed to seamlessly guide your program through each stage of the pharmaceutical journey. Our experts and customer service specialists are available to discuss your cell therapy management needs. Contact us on +1-800-627-5361 (US) or email firstname.lastname@example.org
Marken seamlessly orchestrates distribution of first commercial CAR-T therapy drug product from USA to Japan
28 April 2023
Marken successfully orchestrated the distribution of the first commercial CAR-T therapy drug product from the USA to a hospital in…
Marken’s 24/7 Cell & Gene Control Tower Provides Agile Solution for Critical Shipments
9 February 2023
Marken’s Cell and Gene Control Tower re-routed six critical shipments of CAR-T drug products from Amsterdam to the UK and…
Operational Excellence Overcomes Obstacles to Deliver Critical Autologous Cell Therapy
9 February 2023
Marken utilized operational excellence to deliver a critical autologous cell therapy. Although there were many challenges, Marken was able to…
Marken Successfully Safeguards the Viability of Pharmaceutical Samples Within 42 Hours
4 January 2023
The distribution of critical cell samples requires an agile strategy with contingency planning and regulatory expertise to ensure seamless delivery…
Happy Holidays from Marken
21 December 2022
At Marken, we are passionate about patients – always finding a way to deliver for our clients – on-time, within…
Marken Overcomes Multiple Obstacles To Successfully Deliver Critical Stem Cell Samples Across The Globe
9 December 2022
Stem cell samples require extremely tight 24-hour turnaround times in order to be modified and processed for critical cell therapy…
The Complex Demands of Personalized Medicine Supply Chains.
26 July 2021
Outsourcing-Pharma and Nina Vas, Marken’s Vice President, Clinical Distribution, Cell and Gene Therapy Supply Chain, discuss the specific requirements involved…
Evaluating a Clinical Supply Chain Partner to Meet Your Vaccine Trial Needs.
23 April 2021
It is essential for pharmaceutical companies to evaluate many factors when choosing a clinical supply chain partner. With today’s global…
Decentralized Trials Call for Supply Chain Flexibility: Marken
8 April 2021
Outsourcing-Pharma and Marken’s Vice President, Clinical Distribution, Cell and Gene Therapy Supply Chain, Nina Vas, and Senior Director of Global…
Marken Successfully Ensures On-Time Release Of CAR-T Cell Treatment In Spain
18 March 2021
Overcoming Brexit challenges to coordinate time-sensitive shipments About Marken Marken is a wholly owned subsidiary of UPS and is a…
Marken Makes It Happen COVID-19
13 October 2020
In these unprecedented times, we are coming together to achieve one shared goal: to beat COVID-19. The Marken team is…
Solving Complexities In the Era of the Personalized Medicine Supply Chain.
14 October 2019
Cell and gene therapies are fundamentally different than traditional medicines, from the patient and product journeys to the systems and…